Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:70

Review

Patrono, Carlo¹  Morais, Joao²  Baigent, Colin³  Collet, Jean-Philippe⁴  Fitzgerald, Desmond⁵  Halvorsen, Sigrun^6,7  Rocca, Bianca¹  Siegbahn, Agneta⁸  Storey, Robert F.⁹  Vilahur, Gemma¹⁰ 

[1] Catholic Univ, Sch Med, Dept Pharmacol, Largo F Vito 1, I-00168 Rome, Italy

[2] Santo Andres Hosp, Div Cardiol, Leiria, Portugal

[3] Univ Oxford, Nuffield Dept Populat Hlth, MRC Populat Hlth Res Unit, Oxford, England

[4] Sorbonne Univ Paris 6, Hop Pitie Salpetriere, APHP, ACT Study Grp,Inst Cardiol,INSERM,UMRS 1166, Paris, France

[5] Univ Limerick, Limerick, Ireland

[6] Oslo Univ Hosp Ulleval, Dept Cardiol, Oslo, Norway

[7] Univ Oslo, Oslo, Norway

[8] Uppsala Univ, Clin Chem, Dept Med Sci, Uppsala, Sweden

[9] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England

[10] Hosp Santa Creu & Sant Pau, CiberCV, Cardiovasc Sci Inst ICCC IIB St Pau, Barcelona, Spain

关键词: aspirin;    cangrelor;    clopidogrel;    prasugrel;    ticagrelor;    vorapaxar;   

DOI  :  10.1016/j.jacc.2017.08.037

来源: Elsevier

【 摘 要 】

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures. (C) 2017 by the American College of Cardiology Foundation.

【 授权许可】

Free